Advertisement

Reactions Weekly

, Volume 1731, Issue 1, pp 112–112 | Cite as

Epirubicin/everolimus/paclitaxel

Various toxicities: case report
Case report
  • 15 Downloads

Reference

  1. Shi Y, et al. Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway. Cancer Biology and Medicine 15: 314-321, No. 3, Aug 2018. Available from: URL: http://doi.org/10.20892/j.issn.2095-3941.2017.0188 - China

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations